Drinks bottler Refresco is willing to offer remedies to concerns voiced by Britain’s Competition and Markets Authority (CMA) over the Dutch company’s US$1.25 billion acquisition of Cott’s bottling activities.
The CMA, which has undertaken an initial investigation of the deal, said on Wednesday, January 3, that it had concluded the purchase could result in higher prices or lead to lower quality standards for some juice drinks that both companies supply in the UK.
Refresco said in a separate statement that it was prepared to offer “suitable remedies” to the CMA and would fully cooperate with the watchdog. The regulator had warned that it would refer the deal for an in-depth investigation unless undertakings were made by the Dutch bottling business to assuage its concerns.
“With the clearance we received earlier in the process from the U.S. and Canadian regulatory authorities and the overwhelming support from our shareholders, we are willing to propose remedies to the CMA to address this specific issue and put us on the right track to also obtain clearance in the UK,” said Refresco Chief Executive Hans Roelofs.
Refresco agreed to buy Canada-based Cott’s production business in July in a move that bolsters its operations in the United States, the world’s biggest soft drinks market.
Full Content: Bloomberg BNA
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Top Antitrust Expert Joins Cravath from Paul Weiss
Jan 21, 2025 by
CPI
CMA Chief Removed as UK Government Targets Regulatory Overhaul
Jan 21, 2025 by
CPI
Court Denies Dismissal in Crab Price-Fixing Lawsuit
Jan 21, 2025 by
CPI
TikTok Stays Online for Now: Trump Floats US Ownership Deal
Jan 21, 2025 by
CPI
Hong Kong Watchdog Unveils Compliance Tool for Small Businesses
Jan 21, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Pharmacy Benefit Managers
Jan 20, 2025 by
CPI
Untangling the PBM Mess
Jan 20, 2025 by
Kent Bernard
Using Data, Not Anecdotes, to Analyze Criticisms of Pharmacy Benefit Managers
Jan 20, 2025 by
Dennis Carlton
Vertical Integration and PBMs: What, Me Worry?
Jan 20, 2025 by
Lawton Robert Burns & Bradley Fluegel
The Economics of Benefit Management in Prescription-Drug Markets
Jan 20, 2025 by
Casey B. Mulligan